Abstract
Numerous substances are available for the treatment of metastatic renal cell carcinoma (mRCC). Therefore, medical treatment of patients with mRCC has become a very complex subject. This review summarises clinical studies and typical side-effects of currently available agents that have been approved in Germany. The authors give suggestions for the use of these substances in the different therapy lines.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
